PsyBio continues to increase its presence in the psycho-targeted biosynthesis intellectual property space and remains strongly committed to innovation, development, and technology optimization OXFORD, OH and DENVER, Sept. 19, 2022 /CNW/ – PsyBio Therapeutics Corp. ( TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company focused upon discovery…


Previous articleAlgernon Pharmaceuticals Files for Orphan Designation with the U.S. FDA for Ifenprodil as a Treatment of IPF
Next articleFrom Dendrites to Drug Discovery: An Interview with Dr. Alex Kwan